Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Bulbo-Spinal Atrophy, X-Linked × darolutamide × Clear all

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 20 Prostatic Neoplasms, Castration-Resistant 4 Prostatic Diseases 3 Metastatic Castration-resistant Prostate Cancer 3 Urogenital Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Male Urogenital Diseases 2 Genital Diseases, Male 2 Adenocarcinoma 2 Urogenital Diseases 1 Triple Negative Breast Neoplasms 1 Sleep Initiation and Maintenance Disorders 1 Salivary Gland Neoplasms 1 Prostate Cancer Metastatic 1 Non-metastatic Castration-resistant Prostate Cancer 1 Neoplasms by Site 1 Metastatic Castration-resistant Prostate Neoplasms 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Fatigue 1 Depression 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

abiraterone 2 enzalutamide 1 darolutamide 1 bicalutamide 1 abemaciclib 1 Prednisolone 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07190300 2026-03-02

TulmiSTAR-02

Novartis

Phase 1/2 Recruiting

Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon ⚡